Original Article

When to Worry about Cancer: Concurrent Carcinoma and Recurrence in Borderline Ovarian Tumors

Authors: Mackenzie W. Sullivan, MD, Susan C. Modesitt, MD

Abstract

Objectives: The objectives of this study were to identify and assess the factors associated with concurrent carcinoma and recurrence in women with epithelial borderline ovarian tumors.

Methods: The cancer and pathology databases at a tertiary care academic cancer center were queried for all borderline ovarian tumors from 2005 to 2015. Cases with/without concurrent ovarian carcinoma and with/without recurrence were compared.

Results: A total of 123 women with borderline tumors were identified (mean age 51.3 years). Concurrent carcinoma was present in 31 (25.2%). Women with concurrent carcinoma were significantly more likely to be peri- or postmenopausal, have an elevated CA-125, and have a nonserous histology. Seven (5.7%) women’s cancer recurred at a mean of 23.5 months (mean follow-up 30.0 months). Women with recurrence were more likely to be nonwhite, have concurrent invasive carcinoma, and have had residual disease at the time of surgery.

Conclusions: Epithelial borderline ovarian tumors often co-exist with carcinoma and occur more frequently in postmenopausal women, in women with elevated CA-125, and in tumors with nonserous histology. The presence of any of these factors should alert clinicians to the potential need for comprehensive staging at the time of surgery. The recurrence of borderline tumors is associated with nonwhite race, concurrent carcinoma, and residual disease at initial surgery.
Posted in: Medical Oncology8 Ovarian Disorders And Female Reproductive Health1 Gynecologic Cancer2 Ovarian Disorders3

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Morice P, Uzan C, Fauvet R, et al. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 2012;13:e103-e115.
2. Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol 2005;18(suppl 2):S33-S50.
3. Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001;19:2658-2664.
4. Harter P, Gershenson D, Lhomme C, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer 2014;24( 9 suppl 3 ):S5-S8.
5. Gotlieb WH, Chetrit A, Menczer J, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol 2005;97:780-783.
6. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993;12:120-127.
7. Buttini M, Nicklin JL, Crandon A. Low malignant potential ovarian tumours: a review of 175 consecutive cases. Aust N Z J Obstet Gynaecol 1997;37:100-103.
8. Winter WE, 3rd Kucera PR, Rodgers W, et al. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol 2002;100:671-676.
9. Shah JS, Mackelvie M, Gershenson DM, et al. Accuracy of intraoperative frozen section diagnosis of borderline ovarian tumors by hospital type. J Minim Invasive Gynecol 2019;26:87-93.
10. Gershenson DM, Silva EG, Levy L, et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998;82:1096-1103.